公开(公告)号：US20080076753A1

公开(公告)日：2008-03-27

申请号：US11857891

申请日：2007-09-19

申请人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

发明人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

IPC分类号： A61K31/55 ,  A61P25/00 ,  A61P9/00 ,  C07D471/10 ,  C07D487/10

CPC分类号： C07D487/10

摘要： The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

摘要翻译： 本发明涉及式I的非肽取代的螺杂肼苯并氮平，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心脏功能不全（包括充血性心力衰竭，低钠血症和高血压）的那些。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾功能不全，肾衰竭，糖尿病性肾病，脑水肿， 还公开了脑缺血，中风，血栓形成或保水。

公开(公告)号：US20080076754A1

公开(公告)日：2008-03-27

申请号：US11857954

申请日：2007-09-19

申请人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

发明人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

IPC分类号： A61K31/55 ,  A61P25/00 ,  A61P9/00 ,  C07D471/10 ,  C07D487/10

CPC分类号： C07D487/10

摘要： The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

摘要翻译： 本发明涉及式I的非肽取代的螺杂肼苯并氮平，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心脏功能不全（包括充血性心力衰竭，低钠血症和高血压）的那些。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾衰竭，糖尿病性肾病，脑水肿，脑缺血， 中风，血栓形成或保水性也被公开。